Drug Delivery System for the Anticancer Drug Paclitaxel Using Lipocalin-Type Prostaglandin D Synthase Conjugated to a Tumor-Targeting Peptide.

ABSTRACT: Many drugs currently under development tend to have poor water solubility and large molecular weights, necessitating the development of systems for solubilizing and delivering these drugs to lesion sites. In this study, we attempted to utilize lipocalin-type prostaglandin D synthase (L-PGDS), which has a typical β-barrel structure and secretory lipid transport activity, as a carrier for the anticancer drug paclitaxel (PTX), which has a molecular weight of 854 and extremely low water solubility. Docking simulations and tryptophan residue fluorescence quenching showed that PTX binds to the upper side of the barrel via mainly hydrophobic interactions. To efficiently deliver L-PGDS to cancer cells and promote its internalization, we conjugated the tumor-targeting peptide CRGDK, which binds to

SUBMITTER: Furuta K 

PROVIDER: S-EPMC12824800 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature